Lan, MA
Fei Lan, Brookline, MA US
Patent application number | Description | Published |
---|---|---|
20110021362 | AGENTS FOR STIMULATING ACTIVITY OF METHYL MODIFYING ENZYMES AND METHODS OF USE THEREOF - Agents for stimulating activity of methyl modifying enzymes and methods of using the enzymes in assays to identify enzyme modulators are provided herein. | 01-27-2011 |
Jiang Lan, Waltham, MA US
Patent application number | Description | Published |
---|---|---|
20150163811 | SYSTEM AND METHOD TO DELIVER DIFFERENT SERVICES OVER CELLULAR OR WIFI NETWORKS DEPENDING ON OPERATOR OR USER PREFERENCES - A method includes attaching to a Packet Data Network (PDN) supporting services over a long term evolution (LTE) network to establish a first network connection. The method includes connecting to a wireless local area network, e.g. a WiFi network, to establish a second network connection. The method further includes launching an application accessing at least one of the supported services and receiving a request from the application to switch between the first and second network connections, according to the supported service, e.g. a policy associated with the service. Switching from the first network connection to the second network connections includes connecting to the PDN via an evolved Packet Data Gateway (ePDG). | 06-11-2015 |
Jiang Lan, Walpole, MA US
Patent application number | Description | Published |
---|---|---|
20100138268 | PROGRESS MANAGEMENT PLATFORM - A device receives milestone information and dependency information associated with a project, generates a milestone flow chart based on the milestone information and the dependency information, and represents one or more milestones, in the milestone flow chart, with one or more nodes. The device also represents one or more dependencies among the one or more milestones with one or more directed arcs provided between corresponding nodes of the one or more nodes, and calculates a critical path associated with the one or more milestones. The device further represents the critical path with bolded directed arcs provided between corresponding nodes of the one or more nodes, and provides the milestone flow chart, including the representations of the one or more milestones, the one or more dependencies, and the critical path, for display. | 06-03-2010 |
Ruoxi Lan, Arlington, MA US
Patent application number | Description | Published |
---|---|---|
20090137817 | SPATIALLY-DEFINED MACROCYCLIC COMPOUNDS USEFUL FOR DRUG DISCOVERY - Novel spatially-defined macrocyclic compounds containing specific conformational control elements are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor. | 05-28-2009 |
Ruoxi Lan, Waltham, MA US
Patent application number | Description | Published |
---|---|---|
20110282056 | PROTEIN KINASE INHIBITORS AND USE THEREOF - Disclosed are compounds according to Formula I: | 11-17-2011 |
20120046269 | Novel Amino Azaheterocyclic Carboxamides - The invention provides novel substituted amino azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 02-23-2012 |
20120190654 | NOVEL BICYCLIC UREA COMPOUNDS - The invention provides novel substituted azaheterocyclic compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 07-26-2012 |
20120277228 | Novel Azaheterocyclic Compounds - The invention provides novel substituted azaheterocyclic compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 11-01-2012 |
20130137677 | Bicyclic Azaheterocyclic Carboxamides - The invention provides novel bicyclic azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 05-30-2013 |
20140107156 | Novel Amino Azaheterocyclic Carboxamides - The invention provides novel substituted amino azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 04-17-2014 |
20140309245 | Novel Heterocyclic Carboxamides as Modulators of Kinase Activity - The invention provides novel heterocyclic carboxamide compounds compounds according to Formula (I) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 10-16-2014 |
20140343029 | Novel Imidazole Amines as Modulators of Kinase Activity - The invention provides novel imidazole amine compounds according to Formula (I) and Formula (II) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 11-20-2014 |
20150126484 | AMINOPYRIMIDINE DERIVATIVES FOR USE AS MODULATORS OF KINASE ACTIVITY - The invention provides novel heterocyclic amine compounds according to Formula (I) and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 05-07-2015 |
Tao Lan, Winchester, MA US
Patent application number | Description | Published |
---|---|---|
20110082186 | COMPOSITIONS FOR INHIBITING GENE EXPRESSION AND USES THEREOF - The inventors have examined the means for providing more efficacious gene expression blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of gene expression blocking molecules. These features include the presence of multiple 3′ ends and a linker at the 5′ ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technologies. | 04-07-2011 |
20120016004 | COMPOSITIONS FOR INHIBITING GENE EXPRESSION AND USES THEREOF - The inventors have examined the means for providing more efficacious gene expression blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of gene expression blocking molecules. These features include the presence of multiple 3′ ends and a linker at the 5′ ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technologies. | 01-19-2012 |
20120034248 | NOVEL AGONISTS OF TOLL-LIKE RECEPTOR 3 AND METHODS OF THEIR USE - TLR3 agonist compounds, compositions and methods are provided for stimulating the activity of TLR3. The compositions comprise oligonucleotide-based compounds that bind to and activate TLR3. The compositions may also comprise oligonucleotide-based compounds that bind to and activate TLR3 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for stimulation of TLR3 activity and for prevention or treatment of diseases wherein modulation of TLR3 activity would be beneficial are provided. | 02-09-2012 |
20120183530 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS - The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8. | 07-19-2012 |
20130142778 | COMPOSITIONS FOR INHIBITING GENE EXPRESSION AND USES THEREOF - The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3′ ends and a linker at the 5′ ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology. | 06-06-2013 |
20150044196 | Compositions for Inhibiting Gene Expression and Uses Thereof - The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3′ ends and a linker at the 5′ ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology. | 02-12-2015 |
Tao Lan, Arlington, MA US
Patent application number | Description | Published |
---|---|---|
20090053205 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS - The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8. | 02-26-2009 |
20100215642 | SYNTHETIC RNA-BASED AGONISTS OF TLR7 - The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that selectively induce immune modulatory activity through TLR7. | 08-26-2010 |
20130202584 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 - The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8. | 08-08-2013 |
20140308300 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 - The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8. | 10-16-2014 |
Wenjie Lan, Somerville, MA US
Patent application number | Description | Published |
---|---|---|
20150132742 | Microfluidic Devices Formed From Hydrophobic Paper - Microfluidic devices fabricated from paper that has been covalently modified to increase its hydrophobicity, as well as methods of making and using thereof are provided herein. The devices are typically small, portable, flexible, and both easy and inexpensive to fabricate. Microfluidic devices contain a network of microfluidic components, including microfluidic channels, microfluidic chambers, microwells, or combinations thereof, designed to carry, store, mix, react, and/or analyze liquid samples. The microfluidic channels may be open channels, closed channels, or combinations thereof. The microfluidic devices may be used to detect and/or quantify an analyte, such as a small molecules, proteins, lipids polysaccharides, nucleic acids, prokaryotic cells, eukaryotic cells, particles, viruses, metal ions, and combinations thereof. | 05-14-2015 |
Yan Lan, Belmont, MA US
Patent application number | Description | Published |
---|---|---|
20080311655 | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation - Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is used. This consists of first expressing the non-fused p40 IL-12 subunit in a production cell line, followed by or simultaneously expressing in the same cell, a second recombinant fusion protein consisting of the fused polypeptide linked by a peptide bond to the p35 subunit of IL-12. Molecules containing the p35 fusion protein cannot be secreted from the transfected mammalian cell without first complexing in a one to one ratio with the p40 subunit, thus ensuring the production of active heterodimeric fusion proteins. | 12-18-2008 |
20090088561 | ENHANCING THE CIRCULATING HALF-LIFE OF ANTIBODY-BASED FUSION PROTEINS - Disclosed are methods for the genetic construction and expression of antibody-based fusion proteins with enhanced circulating half-lives. The fusion proteins of the present invention lack the ability to bind to immunoglobulin Fc receptors, either as a consequence of the antibody isotype used for fusion protein construction, or through directed mutagenesis of antibody isotypes that normally bind Fc receptors. The fusion proteins of the present invention may also contain a functional domain capable of binding an immunoglobulin protection receptor. | 04-02-2009 |
20100015089 | HETERODIMERIC FUSION PROTEINS USEFUL FOR TARGETED IMMUNE THERAPY AND GENERAL IMMUNE STIMULATION - Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is used. This consists of first expressing the non-fused p40 IL-12 subunit in a production cell line, followed by or simultaneously expressing in the same cell, a second recombinant fusion protein consisting of the fused polypeptide linked by a peptide bond to the p35 subunit of IL-12. Molecules containing the p35 fusion protein cannot be secreted from the transfected mammalian cell without first complexing in a one to one ratio with the p40 subunit, thus ensuring the production of active heterodimeric fusion proteins. | 01-21-2010 |
20100297060 | ENHANCEMENT OF ANTIBODY-CYTOKINE FUSION PROTEIN MEDIATED IMMUNE RESPONSES BY COMBINED TREATMENT WITH IMMUNOCYTOKINE UPTAKE ENHANCING AGENTS - Disclosed are methods and compositions for treating tumors. Disclosed methods and compositions enhance the uptake of immunocytokines into tumors, and are based on a combination of an immunocytokine with an immunocytokine uptake enhancing agent. Disclosed methods and compositions are particularly useful for reducing tumor size and metastasis in a mammal. | 11-25-2010 |
20130017168 | METHODS FOR ENHANCING THE EFFICACY OF IL-2 MEDIATED IMMUNE RESPONSES - Methods directed to enhancing the effectiveness of IL-2 in stimulating the immune system is disclosed. According to one method, an antagonist directed against the CD25 subunit of the high-affinity IL-2 receptor complex is administered in conjunction with IL-2. The CD25 antagonist may be an anti-CD25 antibody. According to another method, an anti-IL-2 antibody is administered in conjunction with IL-2. In another method, a mutant IL-2 with diminished ability to bind the CD25 subunit of the high-affinity IL-2 receptor complex is administered. In another method, an CD4 antagonist is administered in conjunction with IL-2 in order to stimulate the immune system. | 01-17-2013 |
Yanmei Lan, Acton, MA US
Patent application number | Description | Published |
---|---|---|
20140274997 | CEPHALOSPORIN PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions including a cephalosporin disclosed herein as having the structure of formula (III). | 09-18-2014 |
20140303136 | CEFTOLOZANE ANTIBIOTIC COMPOSITIONS - This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions. | 10-09-2014 |
20140309205 | CEFTOLOZANE ANTIBIOTIC COMPOSITIONS - This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions. | 10-16-2014 |
Yucheng Lan, Newton, MA US
Patent application number | Description | Published |
---|---|---|
20080202575 | METHODS FOR HIGH FIGURE-OF-MERIT IN NANOSTRUCTURED THERMOELECTRIC MATERIALS - Thermoelectric materials with high figures of merit, ZT values, are disclosed. In many instances, such materials include nano-sized domains (e.g., nanocrystalline), which are hypothesized to help increase the ZT value of the material (e.g., by increasing phonon scattering due to interfaces at grain boundaries or grain/inclusion boundaries). The ZT value of such materials can be greater than about 1, 1.2, 1.4, 1.5, 1.8, 2 and even higher. Such materials can be manufactured from a thermoelectric starting material by generating nanoparticles therefrom, or mechanically alloyed nanoparticles from elements which can be subsequently consolidated (e.g., via direct current induced hot press) into a new bulk material. Non-limiting examples of starting materials include bismuth, lead, and/or silicon-based materials, which can be alloyed, elemental, and/or doped. Various compositions and methods relating to aspects of nanostructured thermoelectric materials (e.g., modulation doping) are further disclosed. | 08-28-2008 |
20150068574 | METHODS FOR HIGH FIGURE-OF-MERIT IN NANOSTRUCTURED THERMOELECTRIC MATERIALS - Thermoelectric materials with high figures of merit, ZT values, are disclosed. In many instances, such materials include nano-sized domains (e.g., nanocrystalline), which are hypothesized to help increase the ZT value of the material (e.g., by increasing phonon scattering due to interfaces at grain boundaries or grain/inclusion boundaries). The ZT value of such materials can be greater than about 1, 1.2, 1.4, 1.5, 1.8, 2 and even higher. Such materials can be manufactured from a thermoelectric starting material by generating nanoparticles therefrom, or mechanically alloyed nanoparticles from elements which can be subsequently consolidated (e.g., via direct current induced hot press) into a new bulk material. Non-limiting examples of starting materials include bismuth, lead, and/or silicon-based materials, which can be alloyed, elemental, and/or doped. Various compositions and methods relating to aspects of nanostructured theromoelectric materials (e.g., modulation doping) are further disclosed. | 03-12-2015 |
Zhiyuan Lan, Lowell, MA US
Patent application number | Description | Published |
---|---|---|
20150105484 | FLAME RETARDANT THERMOPLASTIC ELASTOMERS FOR EXTRUSION OR INJECTION MOLDING - Disclosed are new compositions consisting of mixtures of flame retardants for thermoplastic elastomers with the addition of phosphinate salt and phosphonate oligomers, polymers or copolymers, and optionally additional flame retardants. The compositions exhibit an excellent combination of processing characteristics, thermal and mechanical properties, and are flame retardant. Further disclosed are articles of manufacture produced from these materials, such as fibers, films, coated substrates, moldings, foams, fiber-reinforced articles, wires, and cables including these compositions, or any combination thereof. | 04-16-2015 |